To view this email as a web page, click here.

High Recurrence Score Linked with Chemotherapy Success in Breast Cancer

The results of the TAILORx trial went against previous ideas that breast cancer patients with a high Oncotype score who needed chemotherapy and endocrine therapy wouldn't fare well.

FDA Grants Breakthrough Therapy Designation to Niraparib for mCRPC

The agency granted breakthrough therapy designation to niraparib for the treatment of men with BRCA1/2-mutant positive metastatic castration-resistant prostate cancer.

IN CASE YOU MISSED IT

Risk for Second Primary Malignancy Not Uniform Among DLBCL Survivors

A new study looks into whether disease stage at diagnosis affects the occurrence and location of a second primary malignancy in DLBCL.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.